1. Academic Validation
  2. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors

  • Bioorg Med Chem Lett. 2012 Dec 15;22(24):7653-8. doi: 10.1016/j.bmcl.2012.10.007.
Timothy Forsyth 1 Patrick C Kearney Byung Gyu Kim Henry W B Johnson Naing Aay Arlyn Arcalas David S Brown Vicky Chan Jeff Chen Hongwang Du Sergey Epshteyn Adam A Galan Tai P Huynh Mohamed A Ibrahim Brian Kane Elena S Koltun Grace Mann Lisa E Meyr Matthew S Lee Gary L Lewis Robin T Noguchi Michael Pack Brian H Ridgway Xian Shi Craig S Takeuchi Peiwen Zu James W Leahy John M Nuss Ron Aoyama Stefan Engst Steven B Gendreau Robert Kassees Jia Li Shwu-Hwa Lin Jean-Francois Martini Thomas Stout Philip Tong John Woolfrey Wentao Zhang Peiwen Yu
Affiliations

Affiliation

  • 1 Exelixis, Department of Drug Discovery, 169 Harbor Way, South San Francisco, CA 94083, USA.
Abstract

We report the discovery of a series of 4-aryl-2-aminoalkylpyrimidine derivatives as potent and selective JAK2 inhibitors. High throughput screening of our in-house compound library led to the identification of hit 1, from which optimization resulted in the discovery of highly potent and selective JAK2 inhibitors. Advanced lead 10d demonstrated a significant dose-dependent pharmacodynamic and antitumor effect in a mouse xenograft model. Based upon the desirable profile of 10d (XL019) it was advanced into clinical trials.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-13775
    ≥98.0%, JAK2 抑制剂